HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Cancer Research - United States
doi 10.1158/0008-5472.can-13-2420
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer

Cancer Research
Cancer ResearchOncology
2019English

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Oncotarget
Oncology
2014English

Metabolic Consequences of HIF Silencing in a Triple Negative Human Breast Cancer Xenograft

Oncotarget
Oncology
2018English

Epigenetic Silencing of HIC1 Promotes Epithelial-Mesenchymal Transition and Drives Progression in Esophageal Squamous Cell Carcinoma

Oncotarget
Oncology
2015English

Triple-Negative Breast Cancer

2018English

HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells

PLoS ONE
Multidisciplinary
2013English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

ISL1 Promotes Cancer Progression and Inhibits Cisplatin Sensitivity in Triple-Negative Breast Cancer Cells

International Journal of Molecular Medicine
MedicineGenetics
2018English

Silencing the Roadblocks to Effective Triple-Negative Breast Cancer Treatments by siRNA Nanoparticles

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy